1.78 USD
▲+0.05+1.71%
盘后 1.76 +0.29%
2026-08-03
市值
$262.18M
市盈率
—
EPS
-0.71
股息率
—
52 周区间
0.74 – 2.95
成交量
888.69K
Beta
2.45
目标价
7.49
52W 低 0.7452W 高 2.95
价格走势
公司简介
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u...